This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Educational Activities

Controversies in the Psychopharmacology of Bipolar Disorder

Robert M. Post, MD (Chair); Michael J. Ostacher, MD, MPH, MMSc; and Vivek Singh, MD

Published: November 24, 2014

Article Abstract
‘ ‹’ ‹

Few studies have examined the decision-making process for selecting a mood stabilizer or antipsychotic for patients with bipolar disorder. Despite a lack of evidence regarding their efficacy, conventional unimodal antidepressants continue to be used in bipolar treatment regimens. This article examines pharmacologic principles that can facilitate the evidence-based use of mood stabilizers and antipsychotics in patients with bipolar disorder. Choosing therapies for the maintenance of bipolar disorder, clinical decision making upon observation of a partial response, the use of combination therapies, and benefit/harm considerations when choosing a treatment for bipolar depression will be reviewed.

From the Department of Psychiatry, George Washington University School of Medicine, Washington, DC, and the Bipolar Collaborative Network, Bethesda, Maryland (Dr Post); the Bipolar Disorder and Depression Research Program, Veterans Affairs Palo Alto Health Care System, and the Department of Psychiatry and Behavioral Sciences; Stanford University School of Medicine, Palo Alto, California (Dr Ostacher); and the Department of Psychiatry and the University Hospital Psychiatric Service, University of Texas Health Science Center at San Antonio (Dr Singh).

This CME activity is expired. For more CME activities, visit cme.psychiatrist.com.
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

 

Related Articles

Volume: 75

Quick Links: Bipolar Disorder

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...